@article {Xie2020.01.02.20016352, author = {Guoxiang Xie and Xiaoning Wang and Runmin Wei and Jingye Wang and Aihua Zhao and Tianlu Chen and Yixing Wang and Hua Zhang and Zhun Xiao and Xinzhu Liu and Youping Deng and Linda Wong and Jun Panee and Cynthia Rajani and Yan Ni and Sandi Kwee and Hua Bian and Xin Gao and Ping Liu and Wei Jia}, title = {Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection}, elocation-id = {2020.01.02.20016352}, year = {2020}, doi = {10.1101/2020.01.02.20016352}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background \& Aims Accurate and noninvasive diagnosis and staging of liver fibrosis is essential for effective clinical management of chronic liver disease (CLD). We aimed to identify serum metabolite markers that reliably predict the stage of fibrosis in CLD patients.Methods We quantitatively profiled serum metabolites of participants in 2 independent cohorts. Based on the metabolomics data from Cohort 1 (504 HBV associated liver fibrosis patients and 502 normal controls, NC), we selected a panel of 4 predictive metabolite markers. Consequently, we constructed 3 machine learning models with the 4 metabolite markers using random forest (RF), to differentiate CLD patients from normal controls (NC), to differentiate cirrhosis patients from fibrosis patients, and to differentiate advanced fibrosis from early fibrosis, respectively.Results The panel of 4 metabolite markers consisted of taurocholate, tyrosine, valine, and linoelaidic acid. The RF models of the metabolite panel demonstrated the strongest stratification ability in Cohort 1 to diagnose CLD patients from NC (area under the receiver operating characteristic curve (AUROC) = 0.997 and the precision-recall curve (AUPR) = 0.994), to differentiate fibrosis from cirrhosis (0.941, 0.870), and to stage liver fibrosis (0.918, 0.892). The diagnostic accuracy of the models was further validated in an independent Cohort 2 consisting of 300 CLD patients with chronic HBV infection and 90 NC. The AUCs of the models were consistently higher than APRI, FIB-4 and AST/ALT ratio, with both greater sensitivity and specificity.Conclusion Our study showed that this 4-metabolite panel has potential usefulness in clinical assessments of CLD progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financially supported by the National Key R\&D Program of China (2017YFC0906800), the National Institutes of Health/National Cancer Institute Grant 1U01CA188387-01A1, the National Natural Science Foundation of China (81160439, 81573873), the National Key R\&D Program of China (2017YFC0906800), the Natural Science Foundation of Shanghai, China (14ZR1441400, 12ZR1432300), China Postdoctoral Science Foundation funded project, China (2016T90381, 2015M581652), and E-institutes of Shanghai Municipal Education Commission, China (E03008, 085ZY1205). The funding sources did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data supporting the findings of this study are available within the article and its Supplementary Information files or from the corresponding author upon reasonable request.CLDchronic liver diseaseROCreceiver operating characteristicPRprecision-recallAUROCarea under the ROC curveBAsbile acidsFFAsfree fatty acidsAAsamino acidsHBVhepatitis B virusCisconfidence intervalsC18:2 n6tlinolelaidic acidTCAtaurocholatetyrtyrosineValvalineALTalanine transaminaseASTaspartate transaminaseTBILtotal bilirubinALPalkaline phosphataseGGTgamma-glutamyl transferaseALBAlbuminPALBprealbuminTBATotal bile acidCHEcholinesteraseCREAcreatinineBUNblood urea nitrogenCHOLcholesterolTGTriglycerideHDLCHigh-Density Lipoprotein CholesterolLDLClow-density lipoprotein cholesterolApoAIApolipoprotein A1ApoBApolipoprotein BPTProthrombin TimeFibFibrinogenGLUGlucoseRBCred blood cell countWBCwhite blood cellHCThematocritHGBhemoglobinMCHmean corpuscular hemoglobinMCHCMean corpuscular hemoglobin concentrationMPVMean platelet volumePLTplateletGLBglobin}, URL = {https://www.medrxiv.org/content/early/2020/01/06/2020.01.02.20016352}, eprint = {https://www.medrxiv.org/content/early/2020/01/06/2020.01.02.20016352.full.pdf}, journal = {medRxiv} }